Latest news with #DanishMedicinesAgency
&w=3840&q=100)
Business Standard
13 hours ago
- Business
- Business Standard
Gland Pharma shares rise on GMP nod for Telangana manufacturing unit
Shares of Gland Pharma Ltd. rose over 2 per cent in Monday's intraday session after the company received a Good Manufacturing Practices certification from the Danish Medicines Agency for its Pashamylaram facility in Telangana. The pharmaceutical company's stock rose as much as 2.12 per cent during the day to ₹1898.4 per share, the biggest intraday fall since July 1 this year. The stock pared gains to trade 1.27 per cent higher at ₹1,882.7 apiece, compared to a 0.30 per cent decline in Nifty 50 as of 9:40 AM. Shares of the company trade at the highest level since January 7 this year and currently trade at 4 times the average 30-day trading volume, according to Bloomberg. The counter has risen 5.5 per cent this year, compared to a 6 per cent advance in the benchmark Nifty 50. Gland Pharma has a total market capitalisation of ₹30,893.48 crore. Gland Pharma's Pashamylaram facility gets GMP certification The headcare major said that its Pashamylaram facility has received a 'Good Manufacturing Practices' (GMP) compliance certificate from the Danish Medicines Agency, according to an exchange filing. The certification was granted in connection with marketing authorisations that list manufacturers located outside the European Economic Area (EEA), it said. The approval covers aseptically prepared powder for injection, infusion, and inhalation, strengthening the company's regulatory credentials in European markets. Gland Pharma Q4 results Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year. Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago. About Gland Pharma Gland Pharma is a small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. The firm has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities.
Business Standard
2 days ago
- Business
- Business Standard
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.
Business Standard
3 days ago
- Business
- Business Standard
Gland Pharma's Pashamylaram facility receives GMP certification from Danish Medicines Agency
For aseptically prepared Powder for injection, infusion and inhalation Gland Pharma announced that the Pashamylaram facility of the Company has received certificate of Good Manufacturing Practices (GMP) Compliance from Danish Medicines Agency in connection with Marketing authorizations listing manufacturers located outside of the European Economic Area, for aseptically prepared Powder for injection, infusion and inhalation.
Business Upturn
3 days ago
- Business
- Business Upturn
Gland Pharma gets GMP certification for Pashamylaram facility from Danish Medicines Agency
By Aman Shukla Published on July 11, 2025, 16:07 IST Gland Pharma has announced that its Pashamylaram facility has received a Good Manufacturing Practices (GMP) Compliance Certificate from the Danish Medicines Agency. This certification is crucial for marketing authorizations involving manufacturers outside the European Economic Area (EEA). The approval specifically covers the company's aseptically prepared powder products used for injection, infusion, and inhalation. The recognition underscores Gland Pharma's commitment to maintaining global manufacturing standards and strengthens its position in international markets. In the exchange filings, the company shared, 'This is to inform you that the Pashamylaram Facility of the Company has received certificate of Good Manufacturing Practices (GMP) Compliance from Danish Medicines Agency in connection with Marketing authorizations listing manufacturers located outside of the European Economic Area, for aseptically prepared Powder for injection, infusion and inhalation.' This GMP certification will enable Gland Pharma to continue expanding its reach in Europe and support the export of critical injectable and inhalable formulations. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
